.jpg)
Global Erythropoietin Drugs Market Statistics: USD 17.3 Billion Value by 2032
Erythropoietin Drugs Industry
Summary:
- The global erythropoietin drugs market size reached USD 11.0 Billion in 2023.
- The market is expected to reach USD 17.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032.
- North America leads the market, accounting for the largest erythropoietin drugs market share.
- Biologics accounts for the majority of the market share in the drug class segment, which can be attributed to its ability to mimic the action of natural erythropoietin, stimulating the production of red blood cells in the body.
- Epoetin-alfa holds the largest share in the erythropoietin drugs industry.
- Kidney disorder remain a dominant segment in the market on account of the rising focus on improving the overall well-being of patients.
- Hospitals represent the leading end user segment.
- The rising prevalence of chronic kidney diseases (CKDs) is a primary driver of the erythropoietin drugs market.
- Technological advancements and biosimilar approvals and expansion of cancer treatments are reshaping the erythropoietin drugs market.
Industry Trends and Drivers:
- Rising Prevalence of Chronic Kidney Diseases (CKDS):
Chronic kidney disease is a major cause of anemia, which significantly drives the demand for erythropoietin (EPO) drugs. CKD impairs the kidneys' ability to produce erythropoietin, leading to reduced red blood cell (RBC) production and subsequent anemia. People are increasingly suffering from CKD cases on account of risk factors like diabetes, hypertension, and aging populations. They are preferring medications that assist in enhancing their health. As the prevalence of CKD increases, more patients are being diagnosed with anemia, and healthcare systems are focusing on managing this condition to improve quality of life. EPO drugs are essential in treating anemia associated with CKD, making them a critical part of nephrology care.
- Expansion of Cancer Treatments:
Cancer patients undergoing chemotherapy often develop anemia as a side effect, which EPO drugs are used to treat. With the global increase in cancer cases, along with the wider use of chemotherapy as a standard treatment option, the demand for EPO drugs continues to grow. Chemotherapy damages the bone marrow’s ability to produce RBCs, leading to anemia that requires medical intervention. Moreover, EPO drugs help mitigate fatigue and other anemia-related symptoms in cancer patients, improving their quality of life during treatment. As cancer treatments evolve and survival rates improve, managing chemotherapy-induced anemia is becoming a critical aspect of patient care.
- Technological Advancements and Biosimilar Approvals:
Biosimilars assist in offering a more cost-effective option as compared to traditional branded EPO drugs, increasing their accessibility to a broader patient population, particularly in emerging markets. Advancements in drug formulations and production processes are making EPO therapies more efficient and safer. Regulatory bodies are increasingly approving several biosimilar versions of EPO, which are just as effective as their original counterparts but are more affordable. This is increasing competition in the market, making EPO treatments more available in the market. Apart from this, the rising focus on improving patient access to anemia management solutions is contributing to the market growth.
Request for a sample copy of this report: https://www.imarcgroup.com/erythropoietin-drugs-market/requestsample
Erythropoietin Drugs Market Report Segmentation:
Breakup By Drug Class:
- Biologics
- Biosimilars
Biologics account for the majority of shares, which can be attributed to their ability to mimic the action of natural erythropoietin, stimulating the production of red blood cells (RBCs) in the body.
Breakup By Product Type:
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
Epoetin-alfa dominates the market as it aids in reducing the need for blood transfusions.
Breakup By Application:
- Hematology
- Kidney Disorder
- Cancer
- Others
Kidney disorder represents the majority of shares on account of the rising focus on improving the overall well-being of patients.
Breakup By End User:
- Hospitals
- Homecare
- Specialty Clinics
- Others
Hospitals hold the majority of shares due to their ability to ensure timely and accurate diagnosis, prescription, and administration of erythropoietin drugs.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position owing to a large market for erythropoietin drugs driven by the presence of advanced healthcare infrastructure.
Top Erythropoietin Drugs Market Leaders:
The erythropoietin drugs market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:
- Amgen Inc
- Biocon Limited
- Reddy’s Laboratories Ltd
- Hoffmann-La Roche AG
- Intas Pharmaceuticals Ltd
- Johnson & Johnson
- LG Chem Ltd.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
Comments